|
| 37391056 | Evolution of Symptoms After Ustekinumab Induction Therapy in Patients With Crohn's Disease. | Clin Gastroenterol Hepatol | 2024 |
| 37713528 | Baseline Clinical Factors Are Associated With Risk of Complications in Crohn's Disease: Appraisal of the American Gastroenterological Association Clinical Care Pathway. | Am J Gastroenterol | 2024 |
| 37743037 | Vedolizumab, Adalimumab, and Methotrexate Combination Therapy in Crohn's Disease (EXPLORER). | Clin Gastroenterol Hepatol | 2024 |
| 37743039 | Washout Periods in Inflammatory Bowel Disease Trials: A Systematic Literature Review and Proposed Solutions. | Clin Gastroenterol Hepatol | 2024 |
| 38095692 | Efficacy and Safety of Ustekinumab for Ulcerative Colitis Through 4 Years: Final Results of the UNIFI Long-Term Maintenance Study. | Am J Gastroenterol | 2024 |
| 36377259 | Crohn's disease shared decision making intervention leads to more patients choosing combination therapy: a cluster randomised controlled trial. | Aliment Pharmacol Ther | 2023 |
| 37670487 | Comparison of treatment effect between phase 2 and phase 3 trials in patients with inflammatory bowel disease. | United European Gastroenterol J | 2023 |
| 37962770 | Qualitative and psychometric evaluation of the PROMIS®-Fatigue SF-7a scale to assess fatigue in patients with moderately to severely active inflammatory bowel disease. | J Patient Rep Outcomes | 2023 |
| 38056798 | Reliability and Responsiveness of Histologic Indices for the Assessment of Crohn's Disease Activity. | Clin Gastroenterol Hepatol | 2023 |
| 38034882 | Mirikizumab Improves Quality of Life in Patients With Moderately-to-Severely Active Ulcerative Colitis: Results From the Phase 3 LUCENT-1 Induction and LUCENT-2 Maintenance Studies. | Crohns Colitis 360 | 2023 |
| 35590456 | High Prevalence of Malnutrition and Micronutrient Deficiencies in Patients With Inflammatory Bowel Disease Early in Disease Course. | Inflamm Bowel Dis | 2023 |
| 37051722 | Review article: Putting some muscle into sarcopenia-the pathogenesis, assessment and clinical impact of muscle loss in patients with inflammatory bowel disease. | Aliment Pharmacol Ther | 2023 |
| 37379135 | Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis. | N Engl J Med | 2023 |
| 37378711 | Efficacy and Safety of IL-12/23 and IL-23 Inhibitors for Crohn's Disease: Systematic Review and Meta-Analysis. | Dig Dis Sci | 2023 |
| 37308036 | Standardizing Scoring Conventions for Crohn's Disease Endoscopy: An International RAND/UCLA Appropriateness Study. | Clin Gastroenterol Hepatol | 2023 |
| 37436357 | Clinician's Guide to Using Ozanimod for the Treatment of Ulcerative Colitis. | J Crohns Colitis | 2023 |
| 37001911 | Changes in health-related quality of life and associations with improvements in clinical efficacy: a Phase 2 study of mirikizumab in patients with ulcerative colitis. | BMJ Open Gastroenterol | 2023 |
| 37129565 | Obefazimod: A First-in-class Drug for the Treatment of Ulcerative Colitis. | J Crohns Colitis | 2023 |
| 36881820 | Mirikizumab Regulates Genes Involved in Ulcerative Colitis Disease Activity and Anti-TNF Resistance: Results From a Phase 2 Study. | Clin Transl Gastroenterol | 2023 |
| 36871574 | Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies. | Lancet | 2023 |
| 36738762 | Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial. | Lancet Gastroenterol Hepatol | 2023 |
| 36634824 | Anti-Integrin αvβ6 Autoantibodies Are a Novel Biomarker That Antedate Ulcerative Colitis. | Gastroenterology | 2023 |
| 36939629 | A Phase 2b, Randomised, Double-blind, Placebo-controlled, Parallel-arm, Multicenter Study Evaluating the Safety and Efficacy of Tesnatilimab in Patients with Moderately to Severely Active Crohn's Disease. | J Crohns Colitis | 2023 |
| 36149668 | Impact of Care in an Interdisciplinary Inflammatory Bowel Disease Specialty Clinic on Outcomes in Patients Insured with Medicaid. | J Clin Gastroenterol | 2023 |
| 36109152 | Biopsy and blood-based molecular biomarker of inflammation in IBD. | Gut | 2023 |
| 35934286 | Prognostic Value of Fecal Calprotectin to Inform Treat-to-Target Monitoring in Ulcerative Colitis. | Clin Gastroenterol Hepatol | 2023 |
| 36124702 | Tofacitinib for the Treatment of Ulcerative Colitis: An Integrated Summary of up to 7.8 Years of Safety Data from the Global Clinical Programme. | J Crohns Colitis | 2023 |
| 36191274 | The Real-World Effectiveness and Safety of Ustekinumab in the Treatment of Crohn's Disease: Results From the SUCCESS Consortium. | Am J Gastroenterol | 2023 |
| 36287025 | Micronutrients and Their Role in Inflammatory Bowel Disease: Function, Assessment, Supplementation, and Impact on Clinical Outcomes Including Muscle Health. | Inflamm Bowel Dis | 2023 |
| 33039584 | Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis. | Clin Gastroenterol Hepatol | 2022 |
| 35365535 | Proactive infliximab optimisation using a pharmacokinetic dashboard versus standard of care in patients with Crohn's disease: study protocol for a randomised, controlled, multicentre, open-label study (the OPTIMIZE trial). | BMJ Open | 2022 |
| 35553661 | Personalised Medicine with IL-23 Blockers: Myth or Reality? | J Crohns Colitis | 2022 |
| 35413359 | Prospective Cohort Study to Investigate the Safety of Preoperative Tumor Necrosis Factor Inhibitor Exposure in Patients With Inflammatory Bowel Disease Undergoing Intra-abdominal Surgery. | Gastroenterology | 2022 |
| 36513478 | Feasibility and impact of a quality improvement initiative to screen for malnutrition in an Inflammatory Bowel Disease clinic. | Clin Nutr ESPEN | 2022 |
| 36777426 | Impact of Bowel Urgency on Quality of Life and Clinical Outcomes in Patients With Ulcerative Colitis. | Crohns Colitis 360 | 2022 |
| 36506749 | Modified Mayo score <i>versus</i> Mayo score for evaluation of treatment efficacy in patients with ulcerative colitis: data from the tofacitinib OCTAVE program. | Therap Adv Gastroenterol | 2022 |
| 36413450 | Lessons Learned from the Ocean State Crohn's and Colitis Area Registry. | R I Med J (2013) | 2022 |
| 36075249 | ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension. | Lancet Gastroenterol Hepatol | 2022 |
| 36038634 | Large-scale sequencing identifies multiple genes and rare variants associated with Crohn's disease susceptibility. | Nat Genet | 2022 |
| 33827316 | Improved Smoking Cessation Rates in a Pharmacist-Led Program Embedded in an Inflammatory Bowel Disease Specialty Medical Home. | J Pharm Pract | 2022 |
| 33742652 | Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Nonmelanoma Skin Cancer Rates From the Ulcerative Colitis Clinical Program. | Inflamm Bowel Dis | 2022 |
| 33684552 | Efficacy and Safety of Tofacitinib in Ulcerative Colitis Based on Prior Tumor Necrosis Factor Inhibitor Failure Status. | Clin Gastroenterol Hepatol | 2022 |
| 33618023 | Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn's Disease: The IM-UNITI Trial. | Clin Gastroenterol Hepatol | 2022 |
| 35190725 | Ulcerative colitis is characterized by a plasmablast-skewed humoral response associated with disease activity. | Nat Med | 2022 |
| 35189386 | IOIBD Recommendations for Clinical Trials in Ulcerative Proctitis: The PROCTRIAL Consensus. | Clin Gastroenterol Hepatol | 2022 |
| 35183108 | Objective disease activity assessment and therapeutic drug monitoring prior to biologic therapy changes in routine inflammatory bowel disease clinical practice: TARGET-IBD. | BMC Gastroenterol | 2022 |
| 35246988 | Persistence of treatment in patients with ulcerative colitis who responded to tofacitinib therapy: data from the open-label, long-term extension study, OCTAVE open. | Aliment Pharmacol Ther | 2022 |
| 35276329 | Early Symptomatic Improvement After Ustekinumab Therapy in Patients With Ulcerative Colitis: 16-Week Data From the UNIFI Trial. | Clin Gastroenterol Hepatol | 2022 |
| 35239968 | Efficacy and Safety of Maintenance Ustekinumab for Ulcerative Colitis Through 3 Years: UNIFI Long-term Extension. | J Crohns Colitis | 2022 |
| 35051383 | Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: the EXTRA consensus from the International Organization for the Study of Inflammatory Bowel Diseases. | Lancet Gastroenterol Hepatol | 2022 |